Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.64 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.51 |
| ▸ | VEGFA | P15692 | 1/20 | 0.51 |
| ▸ | FLT1 | P17948 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.48 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 2/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
| ▸ | PLAT | P00750 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15630975 | 0.85 | EGLN1 (0.57) | EGLN1RAB9AEGLN3VEGFAFLT1 | |
| SCHEMBL12855992 | 0.84 | CSNK2A1 (0.54) | EGLN1CSNK2A1RAB9AGRM5P2RX1 | |
| SCHEMBL13753913 | 0.83 | CSNK2A1 (0.56) | EGLN1CSNK2A1RAB9AGRM5P2RX1 | |
| SCHEMBL21841256 | 0.82 | EGLN1 (0.55) | EGLN1RAB9AEGLN3VEGFAFLT1 | |
| SCHEMBL12901004 | 0.82 | EGLN1 (0.55) | EGLN1RAB9AKDM4EMEN1LMNA | |
| SCHEMBL12181342 | 0.82 | EGLN1 (0.58) | EGLN1RAB9AEGLN3VEGFAFLT1 | |
| SCHEMBL15630996 | 0.81 | EGLN1 (0.61) | EGLN1RAB9AEGLN3VEGFAFLT1 | |
| SCHEMBL17774860 | 0.80 | KDM4E (0.58) | EGLN1RAB9APOLBKDM4EMEN1 | |
| SCHEMBL8980647 | 0.80 | KDM4E (0.58) | CSNK2A1RAB9AGRM5P2RX1TMPRSS4 | |
| SCHEMBL12245344 | 0.80 | CDK1 (0.63) | EGLN1RAB9AEGLN3VEGFAFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180185440-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR DELIVERY OF BREMELANOTIDE | NOVEN PHARMACEUTICALS, INC. (US) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180185440-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR DELIVERY OF BREMELANOTIDE | VIP, MC2R, SLC10A2 | EGLN1 2818/4885CSNK2A1 2450/4885RAB9A 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.